Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
NCT00250887
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Glioblastoma
Interventions
DRUG:
Gefitnib
Sponsor
University of Zurich